NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q2 2024 (June 30)6holders +2
3new positions
1sold out
$0.06avg. 13F price*
At the end of Q2 2024, 6 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, up 2 from Q1 2024. 3 opened new positions and 1 sold out. The largest holders were Truist Financial Corp. ($2K), Virtu Financial LLC ($2K) and UBS Group AG ($1K).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $4K |
| Exits | 1 | $2K |
All 13F filers, Q1 2024 → Q2 2024: 116,490 shares bought and 13,436 shares sold, net +103,054 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Truist Financial Corp. | — | New | 38,965 | $2K |
| Virtu Financial LLC | — | New | 41,283 | $2K |
| UBS Group AG | — | Add +33930.4% | 23,481 | $1K |
| Wolverine Asset Management LLC | — | Add +590.4% | 14,892 | $895 |
| Bank of America Corp. | — | New | 95 | $6 |
| Tower Research Capital LLC (TRC) | — | No change | 15 | $1 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.